A4 Amyloid Beta (beta-APP) – 0.5MG per vial

Clinical Test Expectation – A4 Amyloid Beta – Human Subjects : Slow memory loss caused by Alzheimers disease and Down Syndrome.
Strength – 0.5MG per vial

Introduction
Amyloid-beta precursor protein is an integral membrane protein expressed in many tissues and concentrated in the synapses of neurons. It functions as a cell surface receptor and has been implicated as a regulator of synapse formation, neural plasticity, antimicrobial activity, and iron export.

A4 Amyloid beta 0.5MG Amyloid beta-protein/amyloid A4 or amyloid beta-peptide is derived from the amyloid beta-precursor protein. Beta amyloid is an extracellular filamentous protein deposit found in the brain. It is the major protein component of amyloid cores, neuritic plaques and is also found as a deposit in neurofibrillary tangles. In man, Alzheimer’s disease is the most common cause of senile dementia and is characterized by abnormal filamentous protein deposits in the brain. Beta amyloid deposits are also detected in Lewy body dementia, Down’s syndrome, amyloidosis (Dutch type) and in the Guam Parkinson-Dementia complex.

Dosing Details – Please visit this link for Dosing instructions : https://researchpeptides.co.za/dosage-instructions/